Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO(TM) (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

PR Newswire December 8, 2014

IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

PR Newswire December 8, 2014

Takeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma

PR Newswire December 8, 2014

Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting

PR Newswire December 8, 2014

Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS(R) (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting

PR Newswire December 8, 2014

Data Presented on REVLIMID® (lenalidomide) Compared with Investigators' Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Business Wire December 8, 2014

REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH

Business Wire December 8, 2014

Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting

Business Wire December 8, 2014

Seattle Genetics Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting

Business Wire December 8, 2014

Juno's CAR T and TCR Investigational Product Candidates Demonstrate Promising Outcomes in Clinical Trials in Patients with B-Cell Cancers

Business Wire December 8, 2014

Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting

GlobeNewswire December 8, 2014

Kadmon Corporation Presents Preclinical Data on KD025 in Chronic Graft-Versus-Host-Disease at American Society of Hematology Annual Meeting

Marketwired December 8, 2014

bluebird bio Announces Data Demonstrating First Four Patients with ?-Thalassemia Major Treated with LentiGlobin(TM) are Transfusion-Free

Business Wire December 8, 2014

New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma

PR Newswire December 8, 2014

Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York

GlobeNewswire December 8, 2014

Research and Markets: 2014-2018 US Critical Care Diagnostic Testing in Ancillary Hospital Locations (ER, OR, ICU): Volume and Sales Forecasts, Emerging Technologies, Competitive Strategies

Business Wire December 8, 2014

17th Annual BIO CEO & Investor Conference to Highlight Industry Financing, Current Policy Trends and the 2015 Market Outlook

Business Wire December 8, 2014

Acetylon Pharmaceuticals Presents Positive Preclinical Data on Selective HDAC1/2 Inhibition for the Treatment of Sickle Cell Disease/?-thalassemia

Business Wire December 8, 2014

New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire December 8, 2014

Global Oncology Biosimilars Market 2014-2018: Key Vendors are Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, Mylan and Sandoz

PR Newswire December 8, 2014